GO:0016519 gastric inhibitory peptide receptor activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0016519 (gastric inhibitory peptide receptor activity) is the molecular function of the GIP receptor (GIPR), a class B G-protein-coupled receptor that binds gastric inhibitory peptide (GIP) and transmits signals across the membrane to activate an associated G-protein.
• GIP is an incretin hormone released from intestinal K cells after nutrient ingestion; its receptor activity is central to glucose-dependent insulin secretion and is a validated target for type 2 diabetes and obesity therapies [5,7].
• Dual GIP/GLP-1 receptor agonists such as tirzepatide were engineered from native GIP sequences to co-activate GIPR and GLP-1R, producing superior glycemic control and weight loss in clinical trials [4,1].
• Triple agonists adding glucagon receptor activity (e.g., retatrutide/LY3437943) further exploit GIPR pharmacology for metabolic disease [6,3].
• GIPR signaling can enhance the therapeutic efficacy of GLP-1, and the mechanistic interplay between these incretin receptors is an active research area [8,2].
• Studying GO:0016519 experimentally requires tools such as receptor binding assays, cAMP reporters, CRISPR knockout/knock-in models, and transcriptomic or proteomic readouts [5,4].
Description
Gastric inhibitory peptide receptor activity (GO:0016519) is a molecular function defined as the combination with gastric inhibitory peptide (GIP) and transmission of the signal across the membrane to activate an associated G-protein. This activity is mediated by the GIP receptor (GIPR), a seven-transmembrane class B G-protein-coupled receptor expressed on pancreatic beta cells, adipocytes, and other tissues. Because GIP is one of the two major incretin hormones, its receptor activity directly influences insulin secretion, glucose homeostasis, and energy balance [5,7]. The term is therefore of high interest to researchers in endocrinology, metabolism, and drug discovery, particularly given the clinical success of GIPR-targeting therapeutics [4,1]. Understanding GO:0016519 at the molecular, cellular, and physiological levels provides a framework for designing experiments that probe incretin biology and metabolic disease mechanisms [2,8].
gastric inhibitory peptide receptor activity At A Glance
| GO ID | GO:0016519 |
|---|---|
| GO term | gastric inhibitory peptide receptor activity |
| Ontology | molecular_function |
| Synonym | GIP receptor activity; glucose-dependent insulinotropic polypeptide receptor activity |
| Definition | Combining with gastric inhibitory peptide (GIP) and transmitting the signal across the membrane to activate an associated G-protein. |
| Major function | Ligand-activated G-protein coupling that mediates incretin signaling in pancreatic beta cells and other tissues. |
| Representative receptor | GIPR (gastric inhibitory peptide receptor) |
| Primary ligand | GIP (gastric inhibitory peptide / glucose-dependent insulinotropic polypeptide) |
| Associated disease relevance | Type 2 diabetes, obesity, and metabolic disorders targeted by dual and triple incretin receptor agonists. |
What Is GO:0016519?
In our own words, GO:0016519 describes the specific molecular function of a receptor that binds gastric inhibitory peptide (GIP) and, upon binding, changes conformation to activate an associated heterotrimeric G-protein inside the cell. This is a signal-transducing activity: the receptor itself does not catalyze a chemical reaction but instead couples ligand recognition to intracellular G-protein activation, typically leading to cAMP accumulation and downstream signaling [5,7]. The term is synonymous with GIP receptor activity and glucose-dependent insulinotropic polypeptide receptor activity.
Why Is gastric inhibitory peptide receptor activity Important in Cell Biology?
GO:0016519 is important because GIP receptor activity is a core component of incretin physiology and a proven drug target for type 2 diabetes and obesity [5,7]. Pharmacological activation of GIPR, especially in combination with GLP-1 receptor activation, produces clinically meaningful improvements in glycemic control and body weight [4,1]. The term also matters for understanding how nutrient-sensing gut hormones coordinate insulin secretion and energy storage, and for interpreting the mechanisms of next-generation multi-agonists such as retatrutide [6,3]. Researchers studying metabolic disease, receptor pharmacology, and GPCR signaling therefore need a precise definition of this activity to design and interpret experiments [8,2].
• GIP receptor activity mediates glucose-dependent insulinotropic signaling in pancreatic beta cells.
• It is one of the two principal incretin receptor activities, alongside GLP-1 receptor activity [5,7].
• Dual GIP/GLP-1 receptor agonists such as tirzepatide rely on GIPR engagement for their metabolic effects.
• Clinical trials of tirzepatide demonstrated sustained weight reduction in adults with obesity, highlighting GIPR pharmacology.
• Triple agonists incorporating GIPR activity are being developed for glycemic control and weight loss [6,3].
• GIPR signaling may enhance the therapeutic efficacy of GLP-1 receptor activation.
• The term is relevant to type 2 diabetes pathophysiology and treatment.
• It provides a molecular target for CRISPR-based knockout, knock-in, and overexpression studies [4,5].
• Understanding GIPR activity supports rational design of multi-receptor agonists.
• It links gut hormone biology to systemic metabolic regulation [5,7].
What Happens During gastric inhibitory peptide receptor activity?
Ligand binding and receptor activation
In simple terms: GIP docks onto its receptor, flipping a molecular switch inside the cell.
Gastric inhibitory peptide (GIP) is released from intestinal K cells after nutrient intake and binds the extracellular domain of the GIP receptor (GIPR), a class B GPCR. This binding event stabilizes an active receptor conformation that is competent to engage G-proteins [5,7]. The receptor activity defined by GO:0016519 specifically refers to this combination with GIP and the subsequent transmembrane signal transmission.
G-protein coupling and second messenger generation
In simple terms: Once activated, the receptor turns on a G-protein that boosts cAMP inside the cell.
Activated GIPR couples to Gs proteins, stimulating adenylyl cyclase and increasing intracellular cAMP. cAMP then activates protein kinase A and other effectors that promote insulin secretion and other cellular responses [5,7]. This G-protein activation step is the defining output of GO:0016519.
Downstream metabolic effects
In simple terms: The signal ultimately helps the body release insulin and manage nutrients.
In pancreatic beta cells, GIPR signaling amplifies glucose-dependent insulin secretion [5,7]. In adipose tissue and other organs, GIPR activity contributes to lipid and energy metabolism. These physiological outcomes are the reason GIPR is targeted by dual and triple incretin agonists [4,6].
Receptor desensitization and regulation
In simple terms: After signaling, the receptor is dialed down to avoid overstimulation.
Like many GPCRs, GIPR undergoes desensitization and internalization following prolonged agonist exposure, a process that regulates the duration and intensity of GIP signaling. This regulation is relevant to the pharmacology of long-acting GIPR agonists used in metabolic disease [4,2].
Key Genes Involved in GO:0016519 gastric inhibitory peptide receptor activity
The following genes and proteins are directly or functionally linked to gastric inhibitory peptide receptor activity (GO:0016519) and its physiological context.
| Gene | Major Role | Research Relevance |
|---|---|---|
| GIPR | Encodes the GIP receptor, the protein that carries GO:0016519 activity | Primary target for knockout, knock-in, and pharmacological studies of incretin signaling [5,4] |
| GIP | Encodes gastric inhibitory peptide, the ligand that binds and activates GIPR | Ligand-side manipulation to study receptor activation and incretin physiology |
| GLP1R | Encodes the GLP-1 receptor, the other major incretin receptor | Comparator and co-target in dual-agonist research [4,8] |
| GCG | Encodes glucagon, the precursor of GIP-like peptides and a triple-agonist component | Relevant to multi-receptor agonist design [6,3] |
| GCGR | Encodes the glucagon receptor | Included in triple agonists with GIPR and GLP-1R activity |
| ADCYAP1R1 | Related GPCR signaling component | Context for GPCR-cAMP signaling comparisons |
| GNAS | Encodes the Gs alpha subunit that couples to GIPR | Essential for G-protein activation downstream of GO:0016519 |
| PRKACA | Catalytic subunit of protein kinase A, a cAMP effector | Downstream readout of GIPR signaling |
| CREB1 | Transcription factor activated by cAMP/PKA | Reporter and functional readout for GIPR activity |
| INS | Insulin gene, a target of incretin signaling | Functional endpoint of GIPR activity in beta cells [5,7] |
| SLC2A2 | Glucose transporter in beta cells | Context for glucose-dependent insulin secretion |
| KCNJ11 | Potassium channel subunit in beta cells | Electrophysiological context of incretin action |
| ABCC8 | Sulfonylurea receptor subunit | Beta-cell excitability context |
| PCSK1 | Prohormone convertase involved in peptide processing | Relevant to incretin peptide maturation |
| DPP4 | Dipeptidyl peptidase-4, degrades GIP and GLP-1 | Pharmacological target that modulates endogenous GIP levels [5,7] |
| LEPR | Leptin receptor, linked to energy balance | Adipose and central metabolic context |
| MC4R | Melanocortin 4 receptor, downstream of leptin signaling | Central energy balance context for incretin therapies |
| GIPR-AS1 | Antisense transcript at the GIPR locus | Potential regulatory RNA for GIPR expression studies |
How Is gastric inhibitory peptide receptor activity Regulated?
GIP receptor activity is regulated at multiple levels. Ligand availability is controlled by nutrient-dependent secretion of GIP from intestinal K cells and by degradation by DPP-4 [5,7]. At the receptor level, prolonged agonist exposure leads to desensitization and internalization, which dampens signaling. Downstream, cAMP/PKA and CREB-dependent transcription shape the cellular response to GIPR activation. Pharmacologically, dual and triple agonists are designed to modulate GIPR activity together with GLP-1R and GCGR to achieve durable metabolic effects [4,6,3]. The interplay between GIPR and GLP-1R signaling is an important regulatory axis in incretin biology [8,2].
gastric inhibitory peptide receptor activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GIPR | Type 2 diabetes and obesity | GIPR knockout and knock-in cell lines; cAMP reporter assays [5,4] |
| GIP | Incretin deficiency states | Ligand overexpression or knockout in enteroendocrine cells |
| GLP1R | Type 2 diabetes and obesity | Dual receptor knockout/knock-in models for agonist studies [4,8] |
| GCGR | Glycemic control and energy balance | Triple agonist response models |
| DPP4 | Incretin degradation and glucose homeostasis | DPP4 knockout or inhibitor-treated cell models [5,7] |
Type 2 diabetes
GIP receptor activity contributes to glucose-dependent insulin secretion, and impaired incretin signaling is a feature of type 2 diabetes [5,7]. Dual GIP/GLP-1 receptor agonists were developed to exploit this biology, with tirzepatide showing clinical proof of concept for glycemic control. The term GO:0016519 is therefore directly relevant to diabetes pathophysiology and treatment.
Obesity and weight management
GIPR activation, particularly in combination with GLP-1R activation, promotes weight reduction in adults with obesity. The SURMOUNT-4 trial demonstrated continued tirzepatide treatment maintained weight reduction, underscoring the clinical importance of GIPR pharmacology. Triple agonists including GIPR activity are also being explored for obesity [6,3].
Metabolic syndrome and related disorders
Because GIPR signaling influences insulin secretion, lipid metabolism, and energy balance, it intersects with broader metabolic syndrome biology [5,8]. Research into how GIP enhances GLP-1 efficacy highlights the therapeutic potential of targeting this receptor activity [8,2].
From gastric inhibitory peptide receptor activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does GIPR mediate GIP-stimulated cAMP production? | GIPR knockout cell line with cAMP reporter |
| How does a point mutation in GIPR affect ligand binding? | Point-mutation knock-in of GIPR [4,5] |
| Can a tagged GIPR be used to track receptor trafficking? | Tagged knock-in of GIPR |
| Does GIPR overexpression enhance incretin signaling? | GIPR overexpression cell model [5,4] |
| What genes are differentially expressed upon GIPR activation? | Transcriptomic profiling of agonist-treated cells [2,8] |
| How do dual agonists affect downstream signaling? | Dual GIPR/GLP1R knockout and rescue models [4,6] |
How to Study the gastric inhibitory peptide receptor activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| cAMP assay | Intracellular cAMP levels | GIPR activation by agonists |
| Ligand binding assay | Receptor-ligand interaction | Characterizing GIPR variants |
| CRISPR knockout | Loss of GIPR function | Causal testing of receptor activity [4,5] |
| CRISPR knock-in | Introduction of specific GIPR mutations | Structure-function studies |
| RNA-seq | Transcriptional changes | Downstream signaling profiling [2,8] |
| Proteomics | Protein expression and modifications | Pathway mapping |
| Insulin secretion assay | Glucose-dependent insulin release | Beta-cell functional readout [5,7] |
| Imaging of tagged receptors | Receptor localization and trafficking | GPCR internalization studies |
Receptor binding and cAMP assays
Ligand binding assays and cAMP accumulation assays are standard methods to measure GIP receptor activity. These readouts directly reflect the G-protein activation step defined by GO:0016519.
CRISPR-based genetic models
Knockout, knock-in, and point-mutation models generated by CRISPR allow causal testing of GIPR function in cell lines [4,5]. Such models are essential for distinguishing receptor-specific effects from off-target pharmacology.
Transcriptomics and proteomics
RNA-seq and proteomics can identify downstream gene expression and protein changes following GIPR activation [2,8]. These approaches help map the broader signaling network linked to incretin receptor activity.
Functional metabolic assays
Insulin secretion assays and glucose handling measurements in beta-cell models provide functional endpoints for GIPR activity [5,7]. These assays connect molecular function to physiological outcomes.
How CRISPR Can Be Used to Study GO:0016519 gastric inhibitory peptide receptor activity
Knockout
CRISPR knockout of GIPR eliminates gastric inhibitory peptide receptor activity, enabling researchers to test whether observed phenotypes depend on this receptor [4,5]. Knockout cell lines are useful for validating agonist specificity and for identifying compensatory pathways.
Point Mutation
Point-mutation knock-in can introduce specific amino acid changes in GIPR to dissect ligand binding and G-protein coupling determinants [4,5]. Such models help link structural features to the activity defined by GO:0016519.
Knock-in
Knock-in of tagged or reporter-linked GIPR allows tracking of receptor expression, localization, and trafficking in live cells. This is valuable for studying receptor desensitization and internalization.
Overexpression
Overexpression of GIPR can amplify signaling responses and is used to study downstream pathway activation and drug efficacy [5,4]. It is particularly useful in cell backgrounds with low endogenous receptor levels.
How EDITGENE Supports gastric inhibitory peptide receptor activity Research
Researchers studying gastric inhibitory peptide receptor activity-related genes often need to determine whether a candidate gene is causally involved in receptor signaling, metabolic regulation, or drug response. EDITGENE provides CRISPR-based cell model services that enable precise genetic manipulation of GIPR and related incretin pathway genes, supporting mechanistic and translational studies.
Contact EDITGENE today to design your custom CRISPR model for gastric inhibitory peptide receptor activity research.
Frequently Asked Questions About gastric inhibitory peptide receptor activity
What is gastric inhibitory peptide receptor activity?
It is the molecular function defined by GO:0016519, in which the GIP receptor binds gastric inhibitory peptide and transmits a signal across the membrane to activate an associated G-protein.
What is the GO ID for gastric inhibitory peptide receptor activity?
The GO ID is GO:0016519.
What genes are involved in gastric inhibitory peptide receptor activity?
The primary gene is GIPR, which encodes the receptor; GIP encodes the ligand, and GNAS encodes the G-protein alpha subunit involved in downstream signaling.
What is the difference between GIP and GLP-1 receptor activity?
GIP and GLP-1 are distinct incretin hormones with separate receptors (GIPR and GLP1R), though both contribute to glucose-dependent insulin secretion and are co-targeted by dual agonists [5,4].
How is gastric inhibitory peptide receptor activity measured?
Common methods include ligand binding assays and cAMP accumulation assays, which reflect G-protein activation.
Why is GIP receptor activity important for diabetes?
GIPR signaling contributes to glucose-dependent insulin secretion, and dual GIP/GLP-1 receptor agonists have shown clinical benefit in type 2 diabetes [4,7].
What drugs target gastric inhibitory peptide receptor activity?
Tirzepatide is a dual GIP/GLP-1 receptor agonist, and retatrutide is a triple agonist including GIPR activity [4,6,3].
Can CRISPR be used to study GIP receptor activity?
Yes, CRISPR knockout, knock-in, and point-mutation models are used to dissect GIPR function and signaling [4,5].
What diseases are linked to GIP receptor activity?
Type 2 diabetes and obesity are the most directly linked conditions, with broader metabolic syndrome relevance [5,7,1].
How does GIP enhance GLP-1 efficacy?
Research suggests GIPR signaling can enhance the therapeutic efficacy of GLP-1 receptor activation, though the mechanisms are still being clarified [8,2].
Conclusion
Gastric inhibitory peptide receptor activity (GO:0016519) is a well-defined molecular function that underpins incretin biology and metabolic disease pharmacology [5,7]. Its clinical relevance is highlighted by the success of dual and triple receptor agonists in diabetes and obesity [4,1,6]. Continued research using CRISPR models, signaling assays, and omics approaches will further clarify how GIPR activity can be harnessed therapeutically [2,8].
References
- 1. Aronne LJ et al.. 2024. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.. JAMA 331(1):38-48 PMID: 38078870
- 2. Liu QK. 2024. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists.. Front Endocrinol (Lausanne) 15:1431292 PMID: 39114288
- 3. Katsi V et al.. 2025. Retatrutide-A Game Changer in Obesity Pharmacotherapy.. Biomolecules 15(6) PMID: 40563436
- 4. Coskun T et al.. 2018. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.. Mol Metab 18:3-14 PMID: 30473097
- 5. Baggio LL et al.. 2007. Biology of incretins: GLP-1 and GIP.. Gastroenterology 132(6):2131-57 PMID: 17498508
- 6. Coskun T et al.. 2022. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept.. Cell Metab 34(9):1234-1247.e9 PMID: 35985340
- 7. Nauck MA et al.. 2023. Incretin hormones and type 2 diabetes.. Diabetologia 66(10):1780-1795 PMID: 37430117
- 8. Samms RJ et al.. 2020. How May GIP Enhance the Therapeutic Efficacy of GLP-1?. Trends Endocrinol Metab 31(6):410-421 PMID: 32396843
